Emanuel Raschi

7.0k total citations · 3 hit papers
169 papers, 4.1k citations indexed

About

Emanuel Raschi is a scholar working on Toxicology, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Emanuel Raschi has authored 169 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Toxicology, 35 papers in Cardiology and Cardiovascular Medicine and 26 papers in Pharmacology. Recurrent topics in Emanuel Raschi's work include Pharmacovigilance and Adverse Drug Reactions (46 papers), Drug-Induced Adverse Reactions (16 papers) and Diabetes Treatment and Management (15 papers). Emanuel Raschi is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (46 papers), Drug-Induced Adverse Reactions (16 papers) and Diabetes Treatment and Management (15 papers). Emanuel Raschi collaborates with scholars based in Italy, United States and France. Emanuel Raschi's co-authors include Fabrizio De Ponti, Elisabetta Poluzzi, Ugo Moretti, Milo Gatti, Michele Fusaroli, Valentina Vasina, Andrea Ardizzoni, Carlo Piccinni, Giulio Marchesini and Francesco Salvo and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Emanuel Raschi

165 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

2024 66 citations Elisabetta Poluzzi, Ugo Moretti et al. SHILAP Revista de lepidopterología profile →
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality

2024 44 citations Georgios Schoretsanitis, Stefan Weiler et al. JAMA Network Open profile →
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure

2025 26 citations Emanuel Raschi et al. profile →

Peers

Countries citing papers authored by Emanuel Raschi

Since Specialization

Citations

This map shows the geographic impact of Emanuel Raschi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emanuel Raschi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emanuel Raschi more than expected).

Fields of papers citing papers by Emanuel Raschi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emanuel Raschi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emanuel Raschi. The network helps show where Emanuel Raschi may publish in the future.

Co-authorship network of co-authors of Emanuel Raschi

This figure shows the co-authorship network connecting the top 25 collaborators of Emanuel Raschi. A scholar is included among the top collaborators of Emanuel Raschi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emanuel Raschi. Emanuel Raschi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal? 2025 ·Obesity Research & Clinical Practice ·(unknown), Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi	6
2	Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons 2025 ·Dermatology and Therapy ·(unknown), (unknown), (unknown), (unknown), M. La Plaça, Rossella Sgarzani, Luca Negosanti, Emanuel Raschi, Michela Starace	1
3	Safety of Hydroxychloroquine: What a Dermatologist Should Know 2025 ·American Journal of Clinical Dermatology ·(unknown), (unknown), M. La Plaça, Bianca Maria Piraccini, Emanuel Raschi, (unknown)	3
4	Symmetrical cutaneous rash in two women 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Michela Starace, (unknown), Emanuel Raschi, (unknown)	1
5	Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality breakdown → 2024 ·JAMA Network Open ·Georgios Schoretsanitis, Stefan Weiler, Corrado Barbui, Emanuel Raschi, Chiara Gastaldon	44
6	The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline 2024 ·Frontiers in Pharmacology ·Michele Fusaroli, Francesco Salvo, Charles Khouri, Emanuel Raschi	7
7	Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System 2024 ·United European Gastroenterology Journal ·Adam Goldman, Emanuel Raschi, Amit Druyan, Κassem Sharif, Adi Lahat, Ilan Ben‐Zvi, Shomron Ben‐Horin	3
8	Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports 2024 ·Journal of Clinical Psychopharmacology ·Michele Fusaroli, Charles Khouri, Elisabetta Poluzzi, Fabrizio De Ponti, Francesco Salvo, Emanuel Raschi	2
9	Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System 2023 ·Journal of Speech Language and Hearing Research ·Michele Fusaroli, Arndis Simonsen, Stephanie A. Borrie, Daniel M. Low, Alberto Parola, Emanuel Raschi, Elisabetta Poluzzi, Riccardo Fusaroli	7
10	Peripheral nervous system adverse events associated with immune checkpoint inhibitors 2023 ·Journal of Neurology ·(unknown), Francesco Gelsomino, Rita Rinaldi, Lorenzo Muccioli, Francesca Comito, Alessandro Di Federico, Andrea De Giglio, Giuseppe Lamberti, Elisa Andrini, Veronica Mollica, Roberto D’Angelo, (unknown), (unknown), (unknown), Emanuel Raschi, Pietro Cortelli, Andrea Ardizzoni, Maria Guarino	28
11	Pharmacovigilance analysis of the Vigibase on neonatal withdrawal syndrome following in utero exposure to antidepressants 2023 ·European Psychiatry ·Chiara Gastaldon, Elena Arzenton, Emanuel Raschi, Olav Spigset, Davide Papola, Giovanni Ostuzzi, Ugo Moretti, Gianluca Trifirò, Corrado Barbui, Georgios Schoretsanitis	0
12	Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells 2022 ·Blood ·Adam Goldman, Emanuel Raschi, Joab Chapman, Bianca Santomasso, Marcelo C. Pasquini, Miguel‐Angel Perales, Roni Shouval	8
13	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study 2021 ·European Journal of Preventive Cardiology ·Adam Goldman, Emanuel Raschi, Tali Cukierman‐Yaffe, Rachel Dankner, Roni Shouval, Michael Shechter, Ilan Ben‐Zvi, Hertzel C. Gerstein, Elad Maor	25
14	Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list 2021 ·Parkinsonism & Related Disorders ·Michele Fusaroli, Emanuel Raschi, Manuela Contin, Luisa Sambati, Marco Menchetti, Angelo Fioritti, Elisabetta Poluzzi	7
15	Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis 2021 ·International Journal of Cancer ·(unknown), Milo Gatti, (unknown), Stefano Cavalieri, Michele Fusaroli, Andrea Ardizzoni, Emanuel Raschi, Lisa Licitra	27
16	Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study 2020 ·SHILAP Revista de lepidopterología ·Carlotta Lunghi, (unknown), (unknown), Emanuel Raschi, (unknown), (unknown), (unknown), Marco Menchetti, Pasquale Roberge, Elisabetta Poluzzi	0
17	Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors 2019 ·BMJ Open Diabetes Research & Care ·Gian Paolo Fadini, Mayur Sarangdhar, Fabrizio De Ponti, Angelo Avogaro, Emanuel Raschi	31
18	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 2019 ·PLoS ONE ·(unknown), Ippazio Cosimo Antonazzo, Carlo Piccinni, Emanuel Raschi, (unknown), Angelo Fioritti, Domenico Berardi, Fabrizio De Ponti, (unknown), Elisabetta Poluzzi	3
19	Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 2018 ·Drug Safety ·Emanuel Raschi, Anna Girardi, Elisabetta Poluzzi, (unknown), Francesca Menniti‐Ippolito, Gabriela Mazzanti, Fabrizio De Ponti	24
20	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications 2014 ·BMC Medicine ·Brian Godman, Max Petzold, Kathleen Bennett, Marion Bennie, Anna Bucsics, Alexander Finlayson, Andrew Martin, (unknown), Jutta Piessnegger, Emanuel Raschi, Steven Simoens, Corinne Zara, Corrado Barbui	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact